Structure-activity and protraction relationship of long-acting glucagon-like peptide-1 derivatives: importance of fatty acid length, polarity, and bulkiness
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
We here report a series of derivatives describing the structure-activity relationship around liraglutide, a once-daily human glucagon-like peptide-1 fatty acid derivative, with respect to potency as well as protraction in vivo. The spacer region between the fatty acid and the peptide is mostly important for potency, whereas the fatty acid or fatty acid mimetic is important for both potency and protraction. The length of the fatty acid is the most important parameter for protraction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“LIR is suitable to be administered once a day, with a tmax of 9~13 hours and t1/2 of 13 hours (80–82).”
From GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach (2023) · cites this paper as [82]
Citations
Cites
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177
Aschner, P., Kipnes, M. S., Lunceford, J. K., Sanchez, M., Mickel, C., Williams-Herman, D. E., & for the Sitagliptin Study 021 Group (2006) · Diabetes Care · doi:10.2337/dc06-0703 · Cited by 880
Knudsen, L. B., Nielsen, P. F., Huusfeldt, P. O., Johansen, N. L., Madsen, K., Pedersen, F. Z., Thøgersen, H., Wilken, M., & Agersø, H. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm9909645 · Cited by 700
Self-citationAugeri, D. J., Robl, J. A., Betebenner, D. A., Magnin, D. R., Khanna, A., Robertson, J. G., Wang, A., Simpkins, L. M., Taunk, P., Huang, Q., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm050261p · Cited by 624
Villhauer, E. B., Brinkman, J. A., Naderi, G. B., Burkey, B. F., Dunning, B. E., Prasad, K., Mangold, B. L., Russell, M. E., & Hughes, T. E. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030091l · Cited by 613
Agersø, H., Jensen, L. B., Elbrønd, B., Rolan, P., & Zdravkovic, M. (2002) · Diabetologia · doi:10.1007/s00125-001-0719-z · Cited by 510
Ahrén, B., Gomis, R., Standl, E., Mills, D., & Schweizer, A. (2004) · Diabetes Care · doi:10.2337/diacare.27.12.2874 · Cited by 487
Vilsbøll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courrèges, J.-P., Verhoeven, R., Bugánová, I., & Madsbad, S. (2007) · Diabetes Care · doi:10.2337/dc06-2593 · Cited by 468
Research works printed but not linked: 9
- Kim D., 2005, J. Med. Chem., 48, 151
- Vilsboll T., 2003, J. Clin. Endocrinol. Metab., 88, 224
- Edwards C. M. B., 2001, Am. J. Physiol. Endocrinol. Metab., 281, E161
- Kim J. G., 2003, Diabetes, 52, 759
- Dong J. Z., 2003, Biopolymers, 71, 2003
- Chou J. Z., 1997, J. Pharm. Sci., 86, 773
- Youn Y. S., 2007, Biochem. Pharmacol., 73, 93
- Degn K. B., 2004, Diabetes, 53, 1194
- DeFronzo R. A., 2005, Diabetes Care, 28, 1100
Cited by
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide
Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L. B., McGuire, J., Steensgaard, D. B., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00726 · Cited by 1,105
Self-citationThe Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970
Self-citationHarnessing albumin as a carrier for cancer therapies
Hoogenboezem, E. N., & Duvall, C. L. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.011 · Cited by 610
“Interestingly, increasing the valency of lipid-modified drugs appears to result in superior albuminbinding and pharmacokinetics, but may hinder potency depending on modification site [60].”
Islet G protein-coupled receptors as potential targets for treatment of type 2 diabetes
Ahrén, B. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2782 · Cited by 419
“This approach was applied in the development of liraglutide (Novo Nordisk), in which a C16 fatty acid is attached to amino acid 20 through a glutamoyl spacer and the lysine in position 28 is exchanged with arginin”
MethodGraaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
“Liraglutide is well tolerated and capable of substantially improving glycemic control with low risk of hypoglycemia and weight loss benefit (Knudsen et al., 2000; Knudsen, 2004; Madsen et al., 2007; Steensgaard et al., 2008; Dharmalingam et al., 2011; Wang et al., 2015). endothelial function.”
BackgroundA clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond
Prasad-Reddy, L., & Isaacs, D. (2015) · Drugs in Context · doi:10.7573/dic.212283 · Cited by 365
“This is primarily a result of a fatty acid substitution in the structure that results in albumin bonding, which extends the duration of action [23].”
Materials and methods for delivery of biological drugs
Zelikin, A. N., Ehrhardt, C., & Healy, A. M. (2016) · Nature Chemistry · doi:10.1038/nchem.2629 · Cited by 315
Recent updates on GLP-1 agonists: Current advancements & challenges
Sharma, D., Verma, S., Vaidya, S., Kalia, K., & Tiwari, V. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.08.088 · Cited by 265
GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
Wang, J.-Y., Wang, Q.-W., Yang, X.-Y., Yang, W., Li, D.-R., Jin, J.-Y., Zhang, H.-C., & Zhang, X.-F. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1085799 · Cited by 248
Malm-Erjefält, M., Bjørnsdottir, I., Vanggaard, J., Helleberg, H., Larsen, U., Oosterhuis, B., van Lier, J. J., Zdravkovic, M., & Olsen, A. K. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034066 · Cited by 201
“This structural change gives a molecular conformation that stabilizes liraglutide against metabolic degradation and enables reversible binding to plasma albumin proteins, leading to further decreased clearance and protracted pharmacologic activity (Knudsen et al., 2000; Madsen et al., 2007).”
BackgroundIngallinella, P., Bianchi, E., Ladwa, N. A., Wang, Y.-J., Hrin, R., Veneziano, M., Bonelli, F., Ketas, T. J., Moore, J. P., Miller, M. D., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0901007106 · Cited by 212
“A favored approach to improve peptide pharmacokinetics is conjugation to lipids (57), which prolongs half-life in circulation through binding to serum proteins.”
BackgroundManandhar, B., & Ahn, J.-M. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm500810s · Cited by 198
Half‐Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation
van Witteloostuijn, S. B., Pedersen, S. L., & Jensen, K. J. (2016) · ChemMedChem · doi:10.1002/cmdc.201600374 · Cited by 183
Battle of GLP-1 delivery technologies
Yu, M., Benjamin, M. M., Srinivasan, S., Morin, E. E., Shishatskaya, E. I., Schwendeman, S. P., & Schwendeman, A. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.009 · Cited by 180
Hattori, Y., Jojima, T., Tomizawa, A., Satoh, H., Hattori, S., Kasai, K., & Hayashi, T. (2010) · Diabetologia · doi:10.1007/s00125-010-1831-8 · Cited by 183
“susceptibility to metabolism by DPP-IV [20] and a high degree of albumin binding of liraglutide (as has been shown for other fatty acid derivatives [21, 22]); moreover, after subcutaneous administration, an additional prolongation of the half-life is mediated by slow absorption of liraglutide from the injection site,…”
RetractedJensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Derving Karsbøl, J., & Pedersen, M. L. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.03.020 · Cited by 182
Manufacturing Peptides as Active Pharmaceutical Ingredients
Zompra, A. A., Galanis, A. S., Werbitzky, O., & Albericio, F. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.23 · Cited by 170
McClean, P. L., & Hölscher, C. (2014) · Neuropharmacology · doi:10.1016/j.neuropharm.2014.07.015 · Cited by 170
A review of lipidation in the development of advanced protein and peptide therapeutics
Menacho‐Melgar, R., Decker, J. S., Hennigan, J. N., & Lynch, M. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.12.032 · Cited by 169
“Linear fatty acids also tend to outperform bulkier albumin binders since the latter category results in either decreased therapeutic potency or half-life [66].”
BackgroundDerivatization with fatty acids in peptide and protein drug discovery
Kurtzhals, P., Østergaard, S., Nishimura, E., & Kjeldsen, T. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00529-w · Cited by 151
The Cardiovascular Effects of GLP‐1 Receptor Agonists
Okerson, T., & CHILTON, R. J. (2010) · Cardiovascular Therapeutics · doi:10.1111/j.1755-5922.2010.00256.x · Cited by 144
Molecular, pharmacological and clinical aspects of liraglutide, a once-daily human GLP-1 analogue
Russell-Jones, D. (2009) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2008.11.018 · Cited by 137
Tølbøl, K. S., Kristiansen, M. N. B., Hansen, H. H., Veidal, S. S., Rigbolt, K. T. G., Gillum, M. P., Jelsing, J., Vrang, N., & Feigh, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i2.179 · Cited by 140
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 135
GLP-1 receptor agonists: A clinical perspective on cardiovascular effects
Mundil, D., Cameron-Vendrig, A., & Husain, M. (2012) · Diabetes and Vascular Disease Research · doi:10.1177/1479164112441526 · Cited by 104
“Abstract The active incretin hormone glucagon-like peptide-1(7-36)amide (GLP-1) is a 30-amino acid peptide that exerts glucoregulatory and insulinotropic actions by functioning as an agonist for the GLP-1 receptor (GLP-1R).”
BackgroundInfluentialPeptide Lipidation – A Synthetic Strategy to Afford Peptide Based Therapeutics
Kowalczyk, R., Harris, P. W. R., Williams, G. M., Yang, S., & Brimble, M. A. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-66095-0_9 · Cited by 109
“It has been reported that the type and composition of the fatty acid attached to a bioactive peptide as well as the nature of the spacer between the peptide chain and the fatty acid moiety influences its activity and plasma half-life (Knudsen et al. 2000; Madsen et al. 2007; Lau et al. 2015).”
BackgroundMethodInfluentialHolscher, C. (2010) · Recent Patents on CNS Drug Discovery · doi:10.2174/157488910791213130 · Cited by 102
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists
Evers, A., Haack, T., Lorenz, M., Bossart, M., Elvert, R., Henkel, B., Stengelin, S., Kurz, M., Glien, M., Dudda, A., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00174 · Cited by 101
Peptide lipidation stabilizes structure to enhance biological function
Ward, B. P., Ottaway, N. L., Perez-Tilve, D., Ma, D., Gelfanov, V. M., Tschöp, M. H., & DiMarchi, R. D. (2013) · Molecular Metabolism · doi:10.1016/j.molmet.2013.08.008 · Cited by 101
“lipidation with alpha-glutamic acid as a spacer) [20].”
Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice
Millar, P., Pathak, N., Parthsarathy, V., Bjourson, A. J., O’Kane, M., Pathak, V., Moffett, R. C., Flatt, P. R., & Gault, V. A. (2017) · Journal of Endocrinology · doi:10.1530/joe-17-0263 · Cited by 102
Protease‐resistant peptide design—empowering nature's fragile warriors against HIV
Weinstock, M. T., Francis, J. N., Redman, J. S., & Kay, M. S. (2012) · Biopolymers · doi:10.1002/bip.22073 · Cited by 97
Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy
Zhang, P., Xu, M., Ding, J., Chen, J., Zhang, T., Huo, L., & Liu, Z. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05591-x · Cited by 96
Emerging dipeptidyl peptidase-4 inhibitors for the treatment of diabetes
Åhrén, B. (2008) · Expert Opinion on Emerging Drugs · doi:10.1517/14728210802584126 · Cited by 102
“These GLP-1 mimetics are DPP-4-resistant compounds, which are either based on modification of the GLP-1 molecule, such as liraglutide [98] , albiglutide [99] or taspoglutide (R 1583 ) [100] , or based on the peptide exendin-4, such as exenatide [27] , CJC-1134 [101] or AVE0010 [102] .”
BackgroundGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutide
Candeias, E., Sebastião, I. C., Cardoso, S. M., Correia, S. C., Carvalho, C. I., Plácido, A. I., Santos, M. S., Oliveira, C. R., Moreira, P. I., & Duarte, A. I. (2015) · World Journal of Diabetes · doi:10.4239/wjd.v6.i6.807 · Cited by 97
Zhang, L., Zhang, L., Li, Y., Li, L., Melchiorsen, J. U., ROSENKILDE, M. M., & Hölscher, C. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191768 · Cited by 83
Ueda, T., Tomita, K., Notsu, Y., Ito, T., Fumoto, M., Takakura, T., Nagatome, H., Takimoto, A., Mihara, S.-I., Togame, H., et al. (2009) · Journal of the American Chemical Society · doi:10.1021/ja900261g · Cited by 75
The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics
Chae, S. Y., Choi, Y. G., Son, S., Jung, S. Y., Lee, D. S., & Lee, K. C. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.01.024 · Cited by 75
Eleven Amino Acid Glucagon-like Peptide-1 Receptor Agonists with Antidiabetic Activity
Mapelli, C., Natarajan, S. I., Meyer, J.-P., Bastos, M. M., Bernatowicz, M. S., Lee, V. G., Pluscec, J., Riexinger, D. J., Sieber-McMaster, E. S., Constantine, K. L., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900752a · Cited by 74
Design, Synthesis, and Biological Activity of Novel Dicoumarol Glucagon-like Peptide 1 Conjugates
Han, J. D. J., Sun, L., Chu, Y., Li, Z., Huang, D., Zhu, X., Qian, H., & Huang, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm4017448 · Cited by 78
Chong, H., Xue, J., Xiong, S., Cong, Z., Ding, X., Zhu, Y., Liu, Z., Chen, T., Feng, Y., He, L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.00288-17 · Cited by 70
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
“The resulting molecular conformation from this structural change protects liraglutide against metabolic degradation by DPP-4 and enables reversible binding to plasma albumin proteins, leading to slower clearance and prolonged pharmacologic activity [58-60].”
BackgroundEngineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery
Yang, P., Zou, H., Chao, E., Sherwood, L., Núñez, V., Keeney, M., Ghartey-Tagoe, E. B., Ding, Z., Quirino, H., Luo, X., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1601653113 · Cited by 73
“(B) Structural model of Ex-4 (9-39) bound to GLP-1 receptor amino-terminal domain (PDB ID code 3C59), with the cross-linking sites colored in yellow.”
BackgroundYang, P., Zou, H., Lee, C., Muppidi, A., Chao, E., Fu, Q., Luo, X., Wang, D., Schultz, P. G., & Shen, W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00768 · Cited by 71
Characterization and impact of peptide physicochemical properties on oral and subcutaneous delivery
Klepach, A., Tran, H., Mohammed, F. A., & ElSayed, M. E. H. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114322 · Cited by 66
DPP‐IV‐resistant, long‐acting oxyntomodulin derivatives
Santoprete, A., Capitò, E., Carrington, P. E., Pocai, A., Finotto, M., Langella, A., Ingallinella, P., Zytko, K., Bufali, S., Cianetti, S., et al. (2011) · Journal of Peptide Science · doi:10.1002/psc.1328 · Cited by 65
A Review on the Association between Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer
Chiu, W.-Y., Shih, S.-R., & Tseng, C.-H. (2012) · Experimental Diabetes Research · doi:10.1155/2012/924168 · Cited by 63
Development of potent and long-acting HIV-1 fusion inhibitors
Chong, H., Wu, X., Su, Y., & He, Y. (2016) · AIDS · doi:10.1097/qad.0000000000001073 · Cited by 63
From lead to market: chemical approaches to transform peptides into therapeutics
Gare, C. L., White, A. M., & Malins, L. R. (2025) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2025.01.009 · Cited by 65
Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity
Knudsen, L. B. (2019) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00048 · Cited by 56
Self-citationIrwin, N., Gault, V. A., & Flatt, P. R. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.513381 · Cited by 57
“This accords well with the view that fatty acid chain length is the most important parameter for protraction of biological action of fatty acid derived peptides [42].”
BackgroundPatterson, J. T., Ottaway, N., Gelfanov, V. M., Smiley, D. L., Pérez–Tilve, D., Pfluger, P. T., Tschöp, M. H., & DiMarchi, R. D. (2010) · ACS Chemical Biology · doi:10.1021/cb1002015 · Cited by 59
Watson, E., Jonker, D. M., Jacobsen, L. V., & Ingwersen, S. H. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009354996 · Cited by 54
“DOI: 10.1177/0091270009354996 Population Pharmacokinetics of Liraglutide, a Once-Daily Human Glucagon-Like Peptide-1 Analog, in Healthy Volunteers and Subjects With Type 2 Diabetes, and Comparison to Twice-Daily Exenatide Estelle Watson, MPhil, Daniël M. Jonker, PhD, Lisbeth V. Jacobsen, MSc, and Steen H. Ingwersen, M…”
BackgroundInfluentialBrain control of energy homeostasis: implications for anti-obesity pharmacotherapy
Johansen, V. B. I., Petersen, J., Lund, J., Mathiesen, C. V., Fenselau, H., & Clemmensen, C. (2025) · Cell · doi:10.1016/j.cell.2025.06.010 · Cited by 53
Hoogenboezem, E. N., Patel, S. S., Lo, J. H., Cavnar, A. B., Babb, L. M., Francini, N., Gbur, E. F., Patil, P., Colazo, J. M., Michell, D. L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45609-0 · Cited by 52
“Humanalbuminhasahighin vivo plasma concentration (35 – 55mg/ml) and long half-life (~19 days), making it an ideal candidate for targeted binding in plasma to serve as an endogenous carrier that increases therapeutic bioavailability 9 .”
Han, J. D. J., Sun, L., Huang, X., Li, Z., Zhang, C., Qian, H., & Huang, W. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12843 · Cited by 54
“…increasing molecular size via chemical conjugation and the introduction of functional moieties that interact physically with biological molecules, such as serum albumin or immunoglobulin (Kim et al., 2003; Green et al., 2004; Madsen et al., 2007; Soltani et al., 2007; Chi et al., 2008b).”
BackgroundInfluentialØstergaard, S., Paulsson, J. F., Kofoed, J., Zosel, F., Olsen, J., Jeppesen, C. B., Spetzler, J. C., Ynddal, L., Schleiss, L. G., Christoffersen, B. Ø., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-00654-3 · Cited by 54
Liraglutide in the management of type 2 diabetes
Wajcberg, E., & Amarah, A. R. (2010) · Drug Design Development and Therapy · doi:10.2147/dddt.s10180 · Cited by 54
Pražienková, V., Holubová, M., Pelantová, H., Bugáňová, M., Pirník, Z., Mikulášková, B., Popelová, A., Blechová, M., Haluzík, M., Železná, B., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183449 · Cited by 51
Incretin‐Based Therapies for Type 2 Diabetes Mellitus: Current Status and Future Prospects
Drab, S. R. (2010) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.30.6.609 · Cited by 51
“This fatty acid structure enables reversible plasma albumin binding, which may contribute to the drug’s partial resistance to DPP-4 degradation and its subsequent prolonged action.(53) The primary mechanism for prolonging the action of liraglutide, however, is thought to be through slowed absorption due to the self-as…”
BackgroundLipopeptides development in cosmetics and pharmaceutical applications: A comprehensive review
Pilz, M., Cavelius, P., Qoura, F., Awad, D., & Brück, T. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108210 · Cited by 51
NK2R control of energy expenditure and feeding to treat metabolic diseases
Sass, F., Ma, T., Ekberg, J. H., Kirigiti, M. A., García‐Ureña, M., Dollet, L., Brown, J. M., Basse, A. L., Yacawych, W. T., Burm, H. B., et al. (2024) · Nature · doi:10.1038/s41586-024-08207-0 · Cited by 53
Liraglutide: clinical pharmacology and considerations for therapy
Sisson, E. M. (2011) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.31.9.896 · Cited by 49
Chong, H., Xue, J., Zhu, Y., Cong, Z., Chen, T., Wei, Q., Qin, C., & He, Y. (2019) · PLoS Pathogens · doi:10.1371/journal.ppat.1007552 · Cited by 48
Han, J. D. J., Huang, X., Sun, L., Li, Z., Qian, H., & Huang, W. (2013) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.05.012 · Cited by 47
Li, Y., Wang, Y., Wei, Q., Zheng, X., Tang, L., Kong, D., & Gong, M. (2015) · Scientific Reports · doi:10.1038/srep18039 · Cited by 48
“Legend: The calculated AUCGLP-1(7-37) shows that the amount of compound 21, 22, 23 and 24 was significantly increased compared to native GLP-1, P 0.01.”
BackgroundInfluentialThe Effect of Lipidation on the Self-Assembly of the Gut-Derived Peptide Hormone PYY 3–36
Hutchinson, J. A., Burholt, S., Hamley, I. W., Lundbäck, A.-K., Uddin, S., dos Santos, A. G., Reza, M., Seitsonen, J. J. T., & Ruokolainen, J. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00286 · Cited by 49
Reiner, J., Berlin, P., Held, J., Thiery, J., Skarbaliene, J., Griffin, J., Russell, W., Eriksson, P., Berner‐Hansen, M., Ehlers, L., et al. (2022) · Journal of Parenteral and Enteral Nutrition · doi:10.1002/jpen.2286 · Cited by 43
King, K., Lin, N.-P., Cheng, R. Y.-H., Chen, G.-H., & Chein, R. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.672097 · Cited by 44
“Most of the lipidations of GLP-1 have no discernible effects on GLP-1R signaling, with a few exceptions, which enhanced the potency of GLP-1 by 6 –7-fold (38).”
BackgroundO'Harte, F. P. M., Parthsarathy, V., Hogg, C., & Flatt, P. R. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202350 · Cited by 44
Douton, J. E., Acharya, N., Stoltzfus, B., Sun, D., Grigson, P. S., & Nyland, J. E. (2022) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000685 · Cited by 43
Trier, S., Linderoth, L., Bjerregaard, S., Andresen, T. L., & Rahbek, U. L. (2014) · PLoS ONE · doi:10.1371/journal.pone.0109939 · Cited by 43
“deleterious effects on biological activity [36].”
Son, S., Chae, S. Y., Kim, C., Choi, Y. G., Jung, S. Y., Lee, S., & Lee, K. C. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901153x · Cited by 44
Glycation of human serum albumin impairs binding to the glucagon-like peptide-1 analogue liraglutide
Soudahome, A. G., Catan, A., Giraud, P., Kouao, S. A., Guérin-Dubourg, A., Debussche, X., Moullec, N. L., Bourdon, E., Bravo, S. B., Paradela‐Dobarro, B., et al. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.815274 · Cited by 43
Contemporary Classification of Glucagon-Like Peptide 1 Receptor Agonists (GLP1RAs)
Kalra, S., Bhattacharya, S., & Kapoor, N. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01113-y · Cited by 46
Bech, E. M., Martos‐Maldonado, M. C., Wismann, P., Sørensen, K. K., van Witteloostuijn, S. B., Thygesen, M. B., Vrang, N., Jelsing, J., Pedersen, S. L., & Jensen, K. J. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00787 · Cited by 42
Ilkowitz, J., Katikaneni, R., Cantwell, M., Ramchandani, N., & Heptulla, R. A. (2016) · Journal of Diabetes Science and Technology · doi:10.1177/1932296816647976 · Cited by 40
“Modifications were made to slow subcutaneous tissue absorption, cause reversible albumin binding, and GLP-1 resistance to inactivation by dipeptidyl peptidase-4.(11,12) Unlike exenatide, with a half-life of 2.”
BackgroundZhou, J., Cai, X., Huang, X., Dai, Y., Sun, L., Zhang, B., Yang, B., Lin, H., Huang, W., & Qian, H. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.07.046 · Cited by 40
Hansen, H. H., Hansen, G., Paulsen, S. J., Vrang, N., Mark, M., Jelsing, J., & Klein, T. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.08.010 · Cited by 41
“GLP-1 and liraglutide exhibit similar GLP-1 receptor affinity but have different physicochemical properties and pharmacokinetics (Madsen et al., 2007); it may therefore be speculated that GLP1 and liraglutide display different brain regional exposure in the DIO rat, causing differential central…”
BackgroundEsposito, S., de Leonibus, M. L., Ingenito, R., Bianchi, E., Orsatti, L., & Monteagudo, E. S. (2018) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2018.07.009 · Cited by 37
Harnessing molecular recognition for localized drug delivery
Liu, R., Zuo, R., & Hudalla, G. A. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.008 · Cited by 37
Dalbøge, L. S., Pedersen, S. L., van Witteloostuijn, S. B., Rasmussen, J. E., Rigbolt, K. T. G., Jensen, K. J., Holst, B., Vrang, N., & Jelsing, J. (2014) · Journal of Peptide Science · doi:10.1002/psc.2727 · Cited by 36
Emerging therapies in the treatment of ‘diabesity’: beyond GLP-1
Tharakan, G., Tan, T., & Bloom, S. R. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.10.003 · Cited by 39
Revisiting amino acids and peptides as anti-glycation agents
Chilukuri, H., Kulkarni, M. J., & Fernandes, M. (2018) · MedChemComm · doi:10.1039/c7md00514h · Cited by 38
Cholesterol‐conjugated peptide antivirals: a path to a rapid response to emerging viral diseases
Pessi, A. (2014) · Journal of Peptide Science · doi:10.1002/psc.2706 · Cited by 37
van Witteloostuijn, S. B., Mannerstedt, K., Wismann, P., Bech, E. M., Thygesen, M. B., Vrang, N., Jelsing, J., Jensen, K. J., & Pedersen, S. L. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00787 · Cited by 34
Wu, Y., Wang, X., Sun, X., Gao, X., Zhang, S., Shen, J., Tian, H., Chen, X., Huang, H., Jiang, S., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.07.009 · Cited by 35
Nissan, N., Allen, M. C., Sabatino, D., & Biggar, K. K. (2024) · Biomolecules · doi:10.3390/biom14101303 · Cited by 36
“Although many therapeutic challenges can be overcome through careful implementation of a variety of structural features, designing novel peptide sequences which fulfil all of the above criteria without compromising their therapeutic potential can be extremely challenging [36].”
BackgroundMäde, V., Bellmann‐Sickert, K., Kaiser, A., Meiler, J., & Beck‐Sickinger, A. G. (2014) · ChemMedChem · doi:10.1002/cmdc.201402235 · Cited by 32
Ma, B., Fuhrmann, J., Henriksen, H. C., Khojasteh, S. C., Li, W., Liu, J., Plise, E. G., Yu, Q., & Cheruzel, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02276 · Cited by 32
Comparison of liraglutide versus other incretin‐related anti‐hyperglycaemic agents
Blonde, L., & Montanya, E. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01575.x · Cited by 34
“Liraglutide differs from human GLP-1 by the attachment of a palmitic acid via a glutamic acid spacer to lysine at position 26 and by the replacement of lysine at position 34 with arginine [18].”
BackgroundKolar, G. R., Grote, S., & Yosten, G. L. C. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12528 · Cited by 31
Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential
AL-Noshokaty, T. M., Abdelhamid, R., Abdelmaksoud, N. M., Khaled, A., Hossam, M., Ahmed, R., Saber, T., Khaled, S., Elshaer, S. S., & Abulsoud, A. I. (2025) · Toxicology Reports · doi:10.1016/j.toxrep.2025.101895 · Cited by 30
Evers, A., Pfeiffer‐Marek, S., Bossart, M., Heubel, C., Stock, U., Tiwari, G., Gebauer, B., Elshorst, B., Pfenninger, A., Lukasczyk, U., et al. (2018) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2018.11.043 · Cited by 30
Design and Synthesis of Potent, Long-Acting Lipidated Relaxin-2 Analogs
Muppidi, A., Lee, S. J., Hsu, C.-H., Zou, H., Lee, C., Pflimlin, E., Mahankali, M., Yang, P., Chao, E., Ahmad, I., et al. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00764 · Cited by 30
Mallart, S., Ingenito, R., Bianchi, E., Bresciani, A., Esposito, S., Gallo, M., Magotti, P., Monteagudo, E., Orsatti, L., Roversi, D., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01533 · Cited by 29
Synthesis, Characterization and Pharmacodynamics of Vitamin‐B12‐Conjugated Glucagon‐Like Peptide‐1
Clardy‐James, S., Chepurny, O. G., Leech, C. A., Holz, G. G., & Doyle, R. P. (2012) · ChemMedChem · doi:10.1002/cmdc.201200461 · Cited by 29
Genetically Encoding a Lipidated Amino Acid for Extension of Protein Half‐Life in vivo
Fu, C., Chen, Q., Zheng, F. J., Yang, L., Li, H., Zhao, Q., Wang, X., Wang, L., & Wang, Q. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201811837 · Cited by 30
Antza, C., Nirantharakumar, K., Doundoulakis, I., Tahrani, A. A., & Toulis, K. A. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s166765 · Cited by 30
“The spacer region (glutamic acid moiety) between the C-18 fatty di-acid sidechain and the peptide is considered to be important for potency, whereas the fatty acid is considered to be important for both potency and protraction.(20) Antza et al Dovepress”
BackgroundDevelopment of highly potent protease‐activated receptor 2 agonists via synthetic lipid tethering
Flynn, A. N., Hoffman, J., Tillu, D. V., Sherwood, C. L., Zhang, Z., Patek, R., Asiedu, M. N., Vágner, J., Price, T. J., & Boitano, S. A. (2013) · The FASEB Journal · doi:10.1096/fj.12-217323 · Cited by 28
“important component of drug function (64).”
Metadata
- Authors
- Madsen, K., Knudsen, L. B., Agersoe, H., Nielsen, P. F., Thøgersen, H., Wilken, M., & Johansen, N. L.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-11-01
- Volume
- 50
- Issue
- 24
- Pages
- 6126-6132
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1978143294
- Cited by
- 244
- References
- 26
- Citations by year
- 2026: 5 · 2025: 20 · 2024: 12 · 2023: 10 · 2022: 13 · 2021: 17 · 2020: 16 · 2019: 12 · 2018: 22 · 2017: 21 · 2016: 18 · 2015: 11 · 2014: 10 · 2013: 13 · 2012: 9
- FWCI
- 7.08
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Keywords
- liraglutide, structure-activity relationship, protraction, spacer region, drug potency, GLP-1 receptor agonists, steric bulkiness
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Liraglutide, Cyclic AMP, Amino Acid Sequence, Animals, Cell Line, Fatty Acids, Cricetinae, Humans, Molecular Sequence Data, Structure-Activity Relationship, Swine, Receptors, Glucagon, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.